Covid-19: Longer gap between Pfizer jabs leads to higher overall antibody levels, study finds

LONDON (Reuters): A longer gap between doses of Pfizer's Covid-19 vaccine leads to higher overall antibody levels than a shorter gap, a British study found on Friday (July 23), but there is a sharp drop in antibody levels after the first dose.

The study might help inform vaccination strategies against the Delta variant, which reduces the effectiveness of a first dose of Covid-19 vaccine even though two doses are still protective.